ArticleMolecular therapy : the journal of the American Society of Gene Therapy2017
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
4 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase IMulticenter Study
In one paragraph
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 368 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
368citing papers in PubMed, 7 pooled it
36.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT03497533 phase1 / phase2unknown statusnot on this mapstarted 2018, after this paper: background citation
TriCAR-T-CD19 Adoptive Immunotherapy for CD19-positive Refractory/Relapsed Non-Hodgkin Lymphoma
Adoptive Immunotherapy for Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cells
NCT03790891 early_phase1unknown statusnot on this mapstarted 2019, after this paper: background citation
Adoptive Immunotherapy for Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell
NCT06045585 early_phase1unknown statusnot on this mapstarted 2023, after this paper: background citation
Early Exploratory Clinical Study of the Safety, Tolerability and Initial Efficacy of JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
Who cites it
368 citing papers in PubMed, 7 syntheses or guidelines pooled it, 606 citations in OpenAlex.
- Pooled it
- Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors.Annals of medicine · 2022Pooled it
- Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2022Pooled it
- Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review.Frontiers in immunology · 2022Pooled it
- Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.The Cochrane database of systematic reviews · 2021Pooled it
- The Association Between Glucocorticoid Administration and the Risk of Impaired Efficacy of Axicabtagene Ciloleucel Treatment: A Systematic Review.Frontiers in immunology · 2021Pooled it
- Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.Nature communications · 2026Trial
- Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma.Blood advances · 2026Trial
- Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial.Nature cancer · 2026Trial
- Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL.Frontiers in immunology · 2026Trial
- Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire.Nature communications · 2025Trial
- Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.Nature medicine · 2022Trial
- Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma.Bone marrow transplantation · 2021Trial
- Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.Cancer medicine · 2021Trial
- Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting.British journal of haematology · 2026Article
- IFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma.Nature communications · 2026Article
- Late Complications After European Medicines Agency-Approved Chimeric Antigen Receptor T-Cell Therapy in Hematological Malignancies: A Scoping Review.Current oncology (Toronto, Ont.) · 2026Article
308 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 1 country.
Frederick L LockeDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA. Electronic address: frederick.locke@moffitt.org.
Sattva S NeelapuDivision of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Nancy L BartlettSiteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.
Tanya SiddiqiDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA.
Julio C ChavezDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Chitra M HosingDivision of Cancer Medicine, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Armin GhobadiSiteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.
Lihua E BuddeDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA.
Adrian BotKite Pharma, Santa Monica, CA 90404, USA.
John M RossiKite Pharma, Santa Monica, CA 90404, USA.
Yizhou JiangKite Pharma, Santa Monica, CA 90404, USA.
Allen X XueKite Pharma, Santa Monica, CA 90404, USA.
Meg EliasKite Pharma, Santa Monica, CA 90404, USA.
Jeff AycockKite Pharma, Santa Monica, CA 90404, USA.
Jeff WiezorekKite Pharma, Santa Monica, CA 90404, USA.
William Y GoKite Pharma, Santa Monica, CA 90404, USA.
Kite (United States) · USCity Of Hope National Medical Center · USMoffitt Cancer Center · USThe University of Texas MD Anderson Cancer Center · USWashington University in St. Louis · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5MBreaking immune tolerance to Survivin in Multiple MyelomaK23CA201594 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI LOCKE, FREDERICK · 2015 to 2019
$821kNCI NIH HHS K23 CA201594NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA076292
Abstract
Outcomes for patients with refractory diffuse large B cell lymphoma (DLBCL) are poor. In the multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an autologous CD3ζ/CD28-based chimeric antigen receptor (CAR) T cell therapy, in patients with refractory DLBCL. Patients received low-dose conditioning chemotherapy with concurrent cyclophosphamide (500 mg/m
Indexed as
Recombinant Fusion ProteinsAdultAgedAntigens, CD19Antineoplastic Combined Chemotherapy ProtocolsBiomarkersCD28 AntigensCombined Modality TherapyDisease ProgressionDrug Resistance, NeoplasmFemaleFollow-Up StudiesHumansImmunophenotypingImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseAntigens, CD19BiomarkersCD28 AntigensReceptor-CD3 Complex, Antigen, T-CellRecombinant Fusion ProteinsCAR TCD19diffuse large B cell lymphomaKTE-C19refractory NHL
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT03497533ClinicalTrials.gov
NCT03720496ClinicalTrials.gov
NCT03790891ClinicalTrials.gov
NCT06045585ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.